HK Inno.N Corp
KOSDAQ:195940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (3.5), the stock would be worth ₩46 306.77 (12% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4 | ₩52 400 |
0%
|
| 3-Year Average | 3.5 | ₩46 306.77 |
-12%
|
| 5-Year Average | 3.7 | ₩48 864.19 |
-7%
|
| Industry Average | 3.8 | ₩50 307.83 |
-4%
|
| Country Average | 5.4 | ₩71 329.32 |
+36%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
HK Inno.N Corp
KOSDAQ:195940
|
1.5T KRW | 4 | 22.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 16.9 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.3 | 27.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.2 | 11.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.4 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.7 |
| Median | 5.4 |
| 70th Percentile | 10.1 |
| Max | 19 609.2 |
Other Multiples
HK Inno.N Corp
Glance View
HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.
